All products for laboratory research use only · Free UK delivery over £75 · COA downloadable before purchase

The Compound Index
Shop now Cart (0)

Research index - 80+ entries

The compound index.
Evidence first.

Browse the index
80+ Entries
8 Categories
4 Evidence grades
COA On every product
30 entries
Category 08

Cellular Ageing

Telomere length, epigenetic biomarkers & senolytic activity

View all 4 entries

Compounds studied in the context of telomere biology, mitochondrial function, thymic signalling, cytoprotection, and epigenetic ageing biomarkers. Evidence ranges from pre-clinical cellular models to compounds with clinical or regulatory histories in specific contexts.

No. 081 Pre-clinical Epitalon Tetrapeptide (Ala-Glu-Asp-Gly). Telomere elongation, pineal regulation, and longevity markers. No. 087 Pre-clinical Humanin Mitochondria-derived peptide. Cytoprotection, IGF-1 signalling, and Alzheimer's research models. No. 083 Phase I / II SS-31 (Elamipretide) Mitochondria-targeted tetrapeptide. Phase II in heart failure and Barth syndrome. Cardiolipin binding. No. 085 Clinical Thymosin Alpha-1 Thymic peptide approved in multiple countries for hepatitis B/C and cancer immunotherapy support.
Category 03

Cognition & Neuropeptides

Neurotrophin signalling, BDNF modulation & neuroprotection

View all 8 entries

Compounds studied for neuropeptide signalling, BDNF modulation, GABAergic activity, and neuroprotection. Several entries focus on Russian and Eastern European clinical research programmes alongside pre-clinical data.

No. 071 Pre-clinical Cortagen Tetrapeptide studied in retinal function, cortical neuroprotection, and tissue regulatory mechanisms. No. 069 Phase I / II Dihexa Hexapeptide derived from angiotensin IV. Studied for HGF/Met signalling and synaptic connectivity. No. 065 Pre-clinical DSIP Delta sleep-inducing peptide. Sleep architecture, stress response, and neuroendocrine modulation. No. 067 Phase II NAD+ Sirtuin activation, mitochondrial bioenergetics, and neurological health across Phase II studies. No. 068 Phase I / II Noopept Dipeptide GVS-111. Studied for BDNF/NGF modulation, neuroprotection, and cognitive enhancement. No. 070 Pre-clinical P21 CNTF-derived peptide studied for neurogenesis and BDNF-like signalling. No. 063 Phase I / II Selank Tuftsin analogue. Anxiolytic effects and memory consolidation via GABAergic modulation. No. 061 Phase II Semax ACTH 4-10 analogue. Studied for BDNF/NGF production, dopamine/serotonin modulation, and synaptic plasticity.
Category 04

Growth Hormone Axis

GHRH receptor binding, GH secretagogue activity & IGF-1 modulation

View all 4 entries

GHRH analogues, GH secretagogues, and IGF-1 modulators studied for receptor selectivity, GH pulse characteristics, and related endocrine pathways. Some compounds have clinical approval histories for specific indications, while others remain pre-clinical or early-stage.

No. 051 Pre-clinical CJC-1295 GHRH analogue with DAC modification for extended half-life. GH pulse amplification. No. 053 Phase I / II Ipamorelin Selective GH secretagogue. High selectivity; no cortisol or prolactin elevation in Phase I/II data. No. 057 Clinical Sermorelin GHRH 1-29 analogue. Previously FDA-approved for paediatric GH deficiency. No. 055 Clinical Tesamorelin FDA-approved GHRH analogue. Approved for HIV-associated lipodystrophy.
Category 02

Metabolic & Adipose

GLP-1 agonism, adipogenesis & mitochondrial function

View all 4 entries

GLP-1 receptor agonists, mitochondrial-derived peptides, and nutrient signalling compounds. These entries cover the underlying science, mechanisms, and published research around metabolic and adipose pathways.

No. 041 Pre-clinical 5-Amino-1MQ NNMT inhibitor. Adipogenesis inhibition and metabolic reprogramming in adipose tissue. No. 034 Phase II AOD-9604 GH fragment analogue 176-191. Lipolysis regulation without IGF-1 axis activation. No. 037 Pre-clinical MOTS-C Mitochondrial-derived peptide. AMPK activation, metabolic regulation, and exercise adaptation. No. 031 Phase II Retatrutide Triple GLP-1/GIP/glucagon agonist. Phase II trials show significant adipose reduction.
Category 01

Recovery & Repair

Connective tissue, wound healing & cellular repair pathways

View all 4 entries

Compounds studied for tissue regeneration, wound closure, and modulation of inflammatory pathways. Most work through extracellular matrix activity, collagen synthesis, or receptor-mediated signalling, with strong pre-clinical representation but limited published human trial data.

No. 014 Pre-clinical BPC-157 Body Protection Compound. Studied for connective tissue, tendon, and GI tract repair mechanisms. No. 019 Pre-clinical GHK-Cu Glycyl-L-histidyl-L-lysine copper complex. Collagen synthesis, wound healing, and skin remodelling. No. 022 Pre-clinical KPV Alpha-MSH C-terminal tripeptide. Anti-inflammatory signalling via MC1R receptor interaction. No. 016 Pre-clinical TB-500 Thymosin Beta-4 fragment. Studied for actin polymerisation and tissue repair signalling cascades.
Category 05

Vitality & Pigmentation

Melanocortin receptor signalling, libido, hormonal drive & pigmentation

View all 6 entries

Compounds studied at melanocortin receptors, kisspeptin pathways, and GnRH signalling. These entries focus on receptor activity, pigmentation pathways, libido-related signalling, and hormonal research models.

No. 096 Phase II Cagrilintide (CAGRI) Long-acting amylin analogue studied in appetite suppression and metabolic regulation. Phase II data in combination with semaglutide. No. 092 Pre-clinical Kisspeptin Endogenous neuropeptide acting on GPR54. Studied for GnRH pulse regulation, hormonal drive, and reproductive axis modulation. No. 093 Pre-clinical Melanotan I / MT-1 Linear α-MSH analogue acting on MC1R. Studied for melanogenesis, photoprotection, and UV-independent pigmentation pathways. No. 094 Pre-clinical Melanotan II / MT-2 Cyclic α-MSH analogue with affinity for MC1R, MC3R, and MC4R. Studied in pigmentation, libido, and appetite modulation. No. 095 Pre-clinical Pinealon Tripeptide (Glu-Asp-Arg). Studied for neuroprotective effects, retinal function, and cognitive preservation in ageing models. No. 091 Pre-clinical PT-141 (Bremelanotide) Cyclic heptapeptide acting on MC3R and MC4R. Studied in libido, vascular function, and sexual dysfunction models.